Markets

Gene therapy biotech MeiraGTx files for an $86 million IPO

An image of a man holding out his hands with many different images
Credit: Shutterstock photo

MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, filed on Monday with the SEC to raise up to $86 million in an initial public offering.

The New York, NY-based company was founded in 2015 and plans to list on the Nasdaq under the symbol MGTX. MeiraGTx Holdings filed confidentially on March 29, 2018. BofA Merrill Lynch, Barclays and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Gene therapy biotech MeiraGTx files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More